Trial Profile

Phase I trial of HBM-4003 for patients with advanced Solid Tumors

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 25 Sep 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Porustobart (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors Harbour BioMed

Most Recent Events

21 Sep 2020 According to a Harbour BioMed media release, the China National Medical Products Administration (NMPA) has approved Investigational New Drug (IND) application for monotherapy therapy for the treatment of patients with advanced solid tumors.
09 Nov 2019 New trial record
04 Nov 2019 According to a Harbour BioMed media release, this trial is expected to begin in the near future.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com